Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Envisia Therapeutics
AddedFeb 15, 2024
UpdatedJun 28, 2026
Envisia Therapeutics

Envisia Therapeutics

Acquired

Envisia Therapeutics, a biotech firm in NC, focuses on researching unmet ocular therapy needs.

HQ
Morrisville, NC, US
Founded
2013
Overview
Compare
Fundraising
Employees

Envisia Therapeutics is a biotechnology company dedicated to addressing unmet medical needs in ophthalmology. Based in Morrisville, North Carolina, the company focuses on developing innovative ocular therapies to improve eye health and treat various eye conditions.

Envisia Therapeutics has made significant strides in the field of ophthalmology, contributing to advancements in eye care. Their research and development efforts have positioned them as a key player in the biotech industry, driving innovation and improving patient outcomes.

Envisia Therapeutics - Similar Companies

Visiox logo

Visiox

visioxpharma.com

EyeCyte logo

EyeCyte

eyecyte.com

Imagen Biotech logo

Imagen Biotech

Nexis Vision logo

Nexis Vision

Ocular Therapeutix logo

Ocular Therapeutix

ocutx.com

Ocular Science logo

Ocular Science

ocularscience.com

Drive Therapeutics logo

Drive Therapeutics

Enlaza Therapeutics logo

Enlaza Therapeutics

TherOptix logo

TherOptix

Ocumension Therapeutics logo

Ocumension Therapeutics

Iview Therapeutics logo

Iview Therapeutics

Envisagenics logo

Envisagenics

envisagenics.com

Forsight Labs logo

Forsight Labs

Seeing Medicines logo

Seeing Medicines

Hyperion DeFi logo

Hyperion DeFi

eyenovia.com

Envisia Therapeutics - Quick Facts

Who are Envisia Therapeutics' competitors?

Companies similar to Envisia Therapeutics include Visiox, EyeCyte, Imagen Biotech and Nexis Vision.

When was Envisia Therapeutics founded?

Envisia Therapeutics was founded in 2013.

Where is Envisia Therapeutics' headquarters located?

Envisia Therapeutics' headquarters is located in Morrisville, NC, US.

When was Envisia Therapeutics' last funding round?

Envisia Therapeutics' most recent funding round was for $16.5M (USD) in March 2016.

How much has Envisia Therapeutics raised to-date?

As of Mar 17, 2016, Envisia Therapeutics has raised a total of $46.1M (USD).

Envisia Therapeutics - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Software
Customer
  • Enterprise
  • Small Business
Main Product
  • Ocular Therapies
Tags
  • Healthtech
  • Research
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
ISIC
  • 7210Research and experimental development on natural sciences and engineering
Show 13 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 623000Nursing and Residential Care Facilities
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 8000Health Services
  • 2830Drugs
  • 8040Offices And Clinics Of Other Health Practitioners
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified